Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of MK-8666 in Participants With Type 2 Diabetes Mellitus (MK-8666-003)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* If female, must be either postmenopausal or surgically sterile~* A Body Mass Index (BMI) ≥18 kg/m\^2 to ≤40 kg/m\^2, inclusive.~* A diagnosis of T2DM~* Drug naïve or is being treated with no more than 2 oral antihyperglycemic agents (thiazolidenediones are excluded)~* Judged to be in good health except for T2DM~* Willing to follow a standard weight maintaining diet throughout the study~* A nonsmoker or has not used nicotine or nicotine-containing products for at least 3 months~Exclusion Criteria:~* A history of clinically significant endocrine (except T2DM), gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, or genitourinary abnormalities or diseases~* A history of myositis or complaints including diffuse myalgias, muscle tenderness, or weakness.~* A history of cancer (malignancy) excepting adequately treated non-melanomatous skin carcinoma or carcinoma in situ of the cervix~* Has clinically unstable diabetic retinopathy, neuropathy, and/or clinical evidence of gastroparesis (frequent nausea, bloating or vomiting, severe gastroesophageal reflux, early satiety)~* A history of type 1 diabetes mellitus and/or history of ketoacidosis~* Taking a medication for a co-morbid condition that is not permitted during the study~* A history of significant multiple and/or severe allergies~* Positive for hepatitis B surface antigen, hepatitis C antibodies or human immunodeficiency virus~* Had major surgery, donated or lost 1 unit of blood within 4 weeks prior to study participation~* Participated in another investigational trial within 4 weeks prior to study participation~* Consumes excessive amounts of alcoholic or caffeine-containing beverages~* A regular user of illicit drugs or a history of drug or alcohol abuse within the past year

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- MK-8666 50 mg (Type: EXPERIMENTAL): MK-8666, 50 mg, oral, once a day (QD) for Days 1 to 14.
- MK-8666 150 mg (Type: EXPERIMENTAL): MK-8666, 150 mg, oral, QD, for Days 1 to 14
- MK-8666 500 mg (Type: EXPERIMENTAL): MK-8666, 500 mg, oral, QD for Days 1 to 14
- Placebo (Type: PLACEBO_COMPARATOR): Placebo, oral, QD for Days 1 to 14

Based on this trial design, predict the completion outcome and termination type (if applicable).